Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biogen Idec (NQ: BIIB ) 205.00 +1.68 (+0.83%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Biogen Idec < Previous 1 2 3 4 5 6 7 8 9 ... 46 47 Next > Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 December 29, 2023 According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023. Via Benzinga Healthcare Heroes: 3 Stocks Innovating in Medicine and Wellness December 27, 2023 Discover these innovative healthcare stocks, backed by the U.S.'s $4.3 trillion health investment, offering stability and high returns. Via InvestorPlace Understanding Biogen's Position In Biotechnology Industry Compared To Competitors December 27, 2023 Via Benzinga If You Invested $100 In This Stock 20 Years Ago, You Would Have $800 Today December 26, 2023 Via Benzinga Top 3 Healthcare Stock Picks for the New Year December 25, 2023 Buy these healthcare stocks for 2024 trading at bargain prices before their earnings inflect higher on improving fundamentals. Via InvestorPlace Looking Into Biogen's Recent Short Interest December 21, 2023 Via Benzinga Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry December 13, 2023 Via Benzinga $1000 Invested In This Stock 20 Years Ago Would Be Worth $7,200 Today December 11, 2023 Via Benzinga 5 Biotech stocks tapping into unmet mental health treatment needs December 20, 2023 Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments. Via MarketBeat Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission December 19, 2023 From Biogen Inc. Via GlobeNewswire CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease December 15, 2023 From Biogen Inc. Via GlobeNewswire The Latest Analyst Ratings for Biogen December 07, 2023 Via Benzinga Comparative Study: Biogen And Industry Competitors In Biotechnology Industry November 28, 2023 Via Benzinga Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today November 16, 2023 Via Benzinga Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential December 14, 2023 The increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight. Via InvestorPlace ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. December 14, 2023 From Sage Therapeutics, Inc. Via Business Wire ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. December 14, 2023 From Biogen Inc. Via GlobeNewswire Tuesday Talk: CPI Data And FOMC Meeting Hold Back Market Breakout December 12, 2023 While the market continues towards making new highs, it is falling short of making a breakout rally. Forthcoming CPI data and the upcoming FOMC meeting may be the catalyst for same. Via Talk Markets Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry November 14, 2023 Via Benzinga Expert Ratings for Biogen November 09, 2023 Via Benzinga Biotech Is Coming Back, Can The Run Last? December 11, 2023 The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. Via Talk Markets 2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond December 09, 2023 These stocks aren't worth the risk. Via The Motley Fool S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets December 07, 2023 Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%). Via Benzinga Topics Stocks Exposures US Equities Why This Biogen Analyst Is Turning Bullish On Alzheimer's Treatment Prospects December 07, 2023 Biogen Inc (NASDAQ: BIIB) has been in focus due to its treatment for early-stage Alzheimer’s disease. Via Benzinga Doing Your Holiday Shopping? These Stocks Might Make Great Gifts December 04, 2023 No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. Via MarketBeat Topics Bonds Exposures Debt Markets Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others November 21, 2023 Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this Via Benzinga Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning November 17, 2023 Biotech companies are edging closer to finding the answers behind Alzheimer's disease. Via Investor's Business Daily Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review November 10, 2023 The major indexes ended long win streaks. Datadog led earnings winners. Via Investor's Business Daily The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks? November 10, 2023 The real competitive battle is about to begin, and it will last a long time. Via The Motley Fool These Analysts Revise Their Forecasts On Biogen After Q3 Results November 09, 2023 Biogen Inc (NASDAQ: BIIB) reported better-than-expected third-quarter earnings. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 46 47 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.